RBC Capital analyst Craig Wong-Pan downgrades ResMed (NYSE:RMD) from Outperform to Sector Perform and raises the price target from $246 to $252.
Adverum Biotechnologies To Present LUNA Preliminary Efficacy And Safety Data At The 47th Annual Meeting Of The Macula Society
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary
